With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

Focused on immunology therapies, this clinical-stage biotech reported significant insider selling amid a challenging year for ...

Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte ...

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

First, let's emphasize that Krystal Biotech has proven to be a fairly innovative company. In 2023, it received approval for ...

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the ...

This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector's two major indexes - the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) - ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...